Sustainable Ecosystem for Bio/Medtech Startups
May 7, 2019
12:30 PM – 5:00 PM
Yale Club Manhattan, Trumbull & Saybrook Room 18th FL
12:30-1:00 PM Network Reception and Lunch
1:00-1:10 PM Opening Remark
"Sustainable Entrepreneurial Ecosystem for Bio/MedTech Startups"
DoHyun Cho, PhD
President and CEO, W Medical Strategy Group | Chairman, New York Health Forum
1:10-2:10 PM Session 1
"U.S. Bio/MedTech Market: Opportunities and Challenges for Foreign Companies"
Among the challenges faced by foreign bio/medtech companies seeking opportunities in the U.S. are FDA approval or clearance, marketing rules, reimbursement, liability exposure, and protectionist impulses. Foreign companies entering the U.S. face competition from some of the largest and most successful pharma and device companies in the world — but the market is vast, the population is aging, and afflicted with chronic disease, the dominance of domestic R&D is eroding, and the tax climate has improved. This panel will address the opportunities and the challenges.
Joe McMenamin, MD, JD, EVP, W Medical Strategy Group (Moderator)
Peter Corless, JD, Partner, Mintz Intellectual Property Practice
Timothy M. Block, PhD, President and Professor, Baruch S. Blumberg Institute and the Hepatitis B Foundation
John Choi, MS, Project Director, Enzychem Lifesciences
2:10-2:30 PM Networking Break
2:30-3:30 PM Session 2
“Sustainable Entrepreneurial Ecosystem for Bio/MedTech Startups”
This panel will explore critical drivers for creation of an entrepreneurial ecosystem for life sciences companies with a special focus on New York City area. We will have panelists from start-up, tech transfer offices and VC’s who will provide important insights on what it takes to build such an ecosystem, some of the challenges and barriers as well as opportunities it presents.
Sundeep Lal, PhD, MBA, CEO and Founder, BioConnexUs (Moderator)
Mark E. Dingle, MBA, CEO, Care 52
William J. Polvino, MD, CEO and Director, Bridge Medicines
Ofra Weinberger, PhD, Director of Licensing, Columbia Technology Ventures
Maria Gotsch, MBA, President and CEO, Partnership Fund for New York City
3:30-4:30 PM Session 3
"Best Practices for a Biotech or MedTech IPO"
This panel is for life sciences companies considering an IPO. The open discussion will explore important areas of consideration and best practices for companies planning to go public, from both an IR/PR perspective, as well as investment banking. How far in advance should companies plan their listing? What types of advisors will you need? Wall Street experts will be available to share their perspectives, tips, and best practices.
Yiqin Shen, Senior Reporter, Mergermarket (Moderator)
William C. Hicks, JD, Co-Chair, Mintz Securities & Capital Markets Practice Group
Kimberly Ha, CEO, KKH Advisors
Bob Ai, PhD, MBA, Managing Director, Solebury Trout
John R. Lieberman, CPA (Managing Director, Perelson Weiner LLP
4:30-5:00 PM Closing & Networking